Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection (PURPOSE 1)

  • STATUS
    Recruiting
  • End date
    Jul 21, 2027
  • participants needed
    5010
  • sponsor
    Gilead Sciences
Updated on 21 August 2023
Accepts healthy volunteers

Summary

The goal of this study is to evaluate the efficacy in preventing HIV infection of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF), in adolescent girls and young women.

Details
Condition Pre-Exposure Prophylaxis of HIV Infection
Treatment F/TAF, F/TDF, Oral Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, Subcutaneous (SC) Lenacapavir (LEN), PTM F/TAF
Clinical Study IdentifierNCT04994509
SponsorGilead Sciences
Last Modified on21 August 2023

Eligibility

Yes No Not Sure

Inclusion Criteria

Incidence Phase
HIV-1 status unknown at initial screening and no prior human immunodeficiency virus ( HIV)-1 testing within the last 3 months
Sexually active (has had > 1 vaginal intercourse within the last 3 months) with cisgender male individuals (CGM)
Randomized Phase
Negative fourth generation HIV-1 antibody (Ab)/antigen (Ag) test confirmed with central HIV-1 testing
Estimated glomerular filtration rate (GFR) ≥ 60 mL/min at screening
Body weight ≥ 35 kg

Exclusion Criteria

Prior receipt of an HIV vaccine
Prior use of long-acting systemic pre-exposure prophylaxis (PrEP)
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note